- Home
- AAP vs RCUS Comparison
AAP vs RCUS Comparison
Compare AAP & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAP | RCUS |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AAP | RCUS |
|---|---|---|
| Price | $42.81 | $25.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $53.50 | $31.90 |
| AVG Volume (30 Days) | ★ 2.4M | 1.4M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $8,601,000,000.00 | $247,000,000.00 |
| Revenue This Year | $0.35 | N/A |
| Revenue Next Year | $2.51 | $45.62 |
| P/E Ratio | $32.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.89 | $12.15 |
| 52 Week High | $65.20 | $31.74 |
Technical Indicators
Market Signals| Indicator | AAP | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 36.79 |
| Support Level | $40.94 | $23.91 |
| Resistance Level | $44.32 | $26.43 |
| Average True Range (ATR) | 1.59 | 1.22 |
| MACD | 0.33 | -0.45 |
| Stochastic Oscillator | 22.48 | 26.16 |
Price Performance
Historical ComparisonAbout AAP Advance Auto Parts Inc.
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.